Giant Cell Tumour of Bone: Morphological, Biological and Histogenetical Aspects

Overview

Journal Int Orthop

Specialty Orthopedics

Date 2006 Oct 3

PMID 17013643

Citations 94

Authors

Mathias Werner

Affiliations

Soon will be listed here.

Abstract

The giant cell tumour of bone (GCT) is a locally aggressive intraosseous neoplasm of obscure biological behaviour. Although well defined in clinical, radiological and histological terms, detailed information on its biological development is still relatively incomplete. The tumoral tissue consists of three cell types--the neoplastic giant cell tumour stromal cells (GCTSC), representing the proliferative fraction, secondarily recruited mononuclear histiocytic cells (MNHC) and multinuclear giant cells (MNGC). These cellular components interact together with factors that have a role in regulating osteoclast function in normal bone tissue (e.g. RANK, RANKL, OPG, M-CSF). Recent publications suggest that the neoplastic stromal cells express differentiation features of mesenchymal stem cells. Further research of the pathogenesis of GCT as well as the complex interactions of its cellular populations may provide the knowledge necessary for developing approaches for a biological-based therapy of this neoplasm.

Citing Articles

Giant Cell Tumor of the Temporal Bone with Direct Invasion into the Middle Ear and Skull Base: A Case Report.

Gupta N, Rubina , Rahman A, Aftab M, Khan R Indian J Otolaryngol Head Neck Surg. 2024; 76(3):2890-2894.

PMID: 38883509 PMC: 11169301. DOI: 10.1007/s12070-024-04550-w.

H3.3-G34W in giant cell tumor of bone functionally aligns with the exon choice repressor hnRNPA1L2.

Lee E, Park Y, Lindroth A Cancer Gene Ther. 2024; 31(8):1177-1185.

PMID: 38811797 PMC: 11327103. DOI: 10.1038/s41417-024-00776-6.

Distal Ulna Giant Cell Tumor treated by Resection without Reconstruction: What were the functional outcomes and review of literature.

Banala T, Salunke A, Bharwani N, Patel K, Maharjan D, Patel S J Orthop. 2024; 53:118-124.

PMID: 38495577 PMC: 10940127. DOI: 10.1016/j.jor.2024.02.040.

Giant Cell Tumor of Bone, Rare Inferior Orbit Location.

Garcia J, Bryson S, Mansueto L Plast Reconstr Surg Glob Open. 2024; 12(2):e5569.

PMID: 38313587 PMC: 10833638. DOI: 10.1097/GOX.0000000000005569.

Human Chorionic Gonadotropin Regulates the Smad Signaling Pathway by Antagonizing TGF-β in Giant Cell Tumor of Bone.

Xu T, Xu S, Ma G, Chang J, Zhang C, Zhou P Recent Pat Anticancer Drug Discov. 2024; 19(2):188-198.

PMID: 38214358 PMC: 10804236. DOI: 10.2174/1574892818666230413082909.

References

Kartsogiannis V, Zhou H, Horwood N, Thomas R, Hards D, Quinn J . Localization of RANKL (receptor activator of NF kappa B ligand) mRNA and protein in skeletal and extraskeletal tissues. Bone. 1999; 25(5):525-34. DOI: 10.1016/s8756-3282(99)00214-8. View

Teot L, OKeefe R, Rosier R, OConnell J, Fox E, Hicks D . Extraosseous primary and recurrent giant cell tumors: transforming growth factor-beta1 and -beta2 expression may explain metaplastic bone formation. Hum Pathol. 1996; 27(7):625-32. DOI: 10.1016/s0046-8177(96)90389-5. View

Atkins G, Haynes D, Graves S, Evdokiou A, Hay S, Bouralexis S . Expression of osteoclast differentiation signals by stromal elements of giant cell tumors. J Bone Miner Res. 2000; 15(4):640-9. DOI: 10.1359/jbmr.2000.15.4.640. View

James I, Dodds R, Olivera D, Nuttall M, Gowen M . Human osteoclastoma-derived stromal cells: correlation of the ability to form mineralized nodules in vitro with formation of bone in vivo. J Bone Miner Res. 1996; 11(10):1453-60. DOI: 10.1002/jbmr.5650111012. View

Simonet W, Lacey D, Dunstan C, Kelley M, Chang M, Luthy R . Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997; 89(2):309-19. DOI: 10.1016/s0092-8674(00)80209-3. View

Brien E, Mirra J, Kessler S, Suen M, Ho J, Yang W . Benign giant cell tumor of bone with osteosarcomatous transformation ("dedifferentiated" primary malignant GCT): report of two cases. Skeletal Radiol. 1997; 26(4):246-55. DOI: 10.1007/s002560050230. View

Cheng J, Johnston J . Giant cell tumor of bone. Prognosis and treatment of pulmonary metastases. Clin Orthop Relat Res. 1997; (338):205-14. DOI: 10.1097/00003086-199705000-00027. View

Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S . Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A. 1998; 95(7):3597-602. PMC: 19881. DOI: 10.1073/pnas.95.7.3597. View

Sunters A, McCluskey J, Grigoriadis A . Control of cell cycle gene expression in bone development and during c-Fos-induced osteosarcoma formation. Dev Genet. 1998; 22(4):386-97. DOI: 10.1002/(SICI)1520-6408(1998)22:4<386::AID-DVG8>3.0.CO;2-2. View

10.

Masui F, Ushigome S, Fujii K . Giant cell tumor of bone: a clinicopathologic study of prognostic factors. Pathol Int. 1998; 48(9):723-9. DOI: 10.1111/j.1440-1827.1998.tb03973.x. View

11.

Zhu X, Hartwick W, Rohan T, Kandel R . Cyclin D1 gene amplification and protein expression in benign breast disease and breast carcinoma. Mod Pathol. 1998; 11(11):1082-8. View

12.

Mori Y, Tsuchiya H, Karita M, Nonomura A, Nojima T, Tomita K . Malignant transformation of a giant cell tumor 25 years after initial treatment. Clin Orthop Relat Res. 2000; (381):185-91. DOI: 10.1097/00003086-200012000-00022. View

13.

Marui T, Yamamoto T, Yoshihara H, Kurosaka M, Mizuno K, Akamatsu T . De novo malignant transformation of giant cell tumor of bone. Skeletal Radiol. 2001; 30(2):104-8. DOI: 10.1007/s002560000305. View

14.

Atkins G, Bouralexis S, Haynes D, Graves S, Geary S, Evdokiou A . Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumors of bone. Bone. 2001; 28(4):370-7. DOI: 10.1016/s8756-3282(01)00404-5. View

15.

Roux S, Amazit L, Meduri G, Guiochon-Mantel A, Milgrom E, Mariette X . RANK (receptor activator of nuclear factor kappa B) and RANK ligand are expressed in giant cell tumors of bone. Am J Clin Pathol. 2002; 117(2):210-6. DOI: 10.1309/BPET-F2PE-P2BD-J3P3. View

16.

Turcotte R, Wunder J, Isler M, Bell R, Schachar N, Masri B . Giant cell tumor of long bone: a Canadian Sarcoma Group study. Clin Orthop Relat Res. 2002; (397):248-58. DOI: 10.1097/00003086-200204000-00029. View

17.

Kumta S, Huang L, Cheng Y, Chow L, Lee K, Zheng M . Expression of VEGF and MMP-9 in giant cell tumor of bone and other osteolytic lesions. Life Sci. 2003; 73(11):1427-36. DOI: 10.1016/s0024-3205(03)00434-x. View

18.

Robinson D, Segal M, Nevo Z . Giant cell tumor of bone. The role of fibroblast growth factor 3 positive mesenchymal stem cells in its pathogenesis. Pathobiology. 2003; 70(6):333-42. DOI: 10.1159/000071273. View

19.

Riminucci M, Kuznetsov S, Cherman N, Corsi A, Bianco P, Robey P . Osteoclastogenesis in fibrous dysplasia of bone: in situ and in vitro analysis of IL-6 expression. Bone. 2003; 33(3):434-42. DOI: 10.1016/s8756-3282(03)00064-4. View

20.

Montero O, Salle M, Guevara R, Olivera P, Maldonado V, Melendez-Zajgla J . Cytogenetic analysis of the mononuclear cell component of giant cell tumors of bone. Cancer Genet Cytogenet. 2003; 146(2):170-2. DOI: 10.1016/s0165-4608(03)00153-5. View